2206
R. HAN ET AL.
Preparation of 4
Imidazole, Boc-cyclen, or morpholine (10 mmoL) and compound 3 (10 mmol) were
placed into a 50 mL round-bottom flask with CH3CN (30 mL) and Na2CO3 (0.5 g). The
reaction mixture was allowed to warm to reflux and stirred 48 h under Ar. The solvent was
removed by rotary evaporation and the residue was chromatographed on a silica gel column
(petroleum ether:AcOEt = 1:1.5) to give pure title compound 4.
1,1,3,3-tetraphenylyloxy-5,5,-bikis[4-(1,4,7,10-(1,4,7-tricarboxylic acid tri-tert-
butyl)- tetraazacyclododecanyl)methylphenoxy]cyclotriphosphazene (4a): yield 77%;
1H NMR (CDCl3): δ 7.49 (dd, 4H, -C6H4, J = 7.6 Hz), 7.39 (t, 4H, -C12H8, J = 6.8 Hz),
7.33–7.28 (m, 12H, -C12H8), 7.08 (d, 4H, -C6H4, J = 8.0 Hz), 3.77 (s, 4H, -CH2-Ph), 3.57
(s, 8H, -CH2-cyclen), 3.39–3.17 (m, 16H, -CH2-cyclen) 2.69 (s, 8H, -CH2-cyclen), 1.43 (t,
54H, -CH3, J = 11.6 Hz); 13C NMR (CDCl3): δ 156.1, 155.6, 155.2, 150.0, 148.0, 133.8,
131.3, 129.7, 129.5, 128.7, 126.0, 121.7, 120.9, 120.8, 79.5, 79.4, 79.2, 56.3, 55.9, 55.3,
50.0, 48.7, 48.0, 47.5, 47.2, 28.6, 28.4; 31P NMR (CDCl3): δ 25.6 (d, -P(O2C12H8)2, J =
92.7 Hz), 9.2 (t, P(-O-C6H4-)2, J = 92 Hz); ESI-MS: m/z 1681 [M+Na]+.
1,1,3,3-tetraphenylyloxy-5,5,-bikis(4-imdazolylmethylphenoxy)cyclotriphospha
1
zene (4b): yield 59.6%; H NMR (CDCl3): δ 7.58 (s, 2H, -N-CH N-), 7.51 (dd, 4H,
-C6H4, J = 7.4 Hz), 7.38–7.29 (m, 12H, -C12H8), 7.18 (d, 4H, -C12H8, J = 8.4Hz), 7.10
(s, 2H, CH-N ), 7.03 (d, 4H, -C6H4, J = 8.0 Hz), 6.91 (s, 2H, -N-CH2 = C-), 5.13
(s, 4H, -CH2-Ph); 13C NMR (CDCl3): δ 150.5, 147.9, 137.3, 133.2, 129.9, 129.7, 129.6,
128.6, 128.5, 126.1, 121.7, 121.6, 119.1; 31P NMR (CDCl3): δ 25.3 (d, P(O2C12H8)2, J =
93.2 Hz); 9.5 (t, P(-O-C6H4-)2, J = 92.3 Hz); ESI-MS: m/z 850 [M+H]+; HR-MS: m/z
found 850.1866 (calcd. 850.1862) [M+H]+.
1,1,3,3-tetraphenylyloxy-5,5-bikis(4-morpholinomethylphenoxy)cyclotriphosph
azene (4c): yield 62.0%; 1H NMR (CDCl3): δ7.51 (dd, 4H, -C6H4, J = 7.6 Hz), 7.40–7.29
(m, 16H, -C12H8), 7.07 (d, 4H, -C6H4, J = 7.6 Hz), 3.69 (t, 8H, CH2-O-, J = 4.4 Hz),
3.51 (s, 4H, -CH2-Ph), 2.54 (t, 8H, N-CH2-C-, J = 4.4 Hz); 13C NMR (CDCl3): δ149.9,
148.0, 134.7, 130.2, 129.5, 128.7, 126.0, 121.0, 121.0, 120.9, 66.9, 62.8, 53.5; 31P NMR
(CDCl3): δ 25.6 (d, -P(O2C12H8)2, J = 92.3 Hz), 9.7 (t, P(-O-C6H4-)2, J = 92.3 Hz);
ESI-MS: m/z 888 [M+H]+, m/z 910 [M+Na]+.
Preparation of 5a
◦
To a solution of 4a (1.68 g, 1 mmol) in dry CH2Cl2 (50 mL) at 0 C, CF3COOH
(15 mL) was added dropwise under N2. The mixture was stirred for 7 h at room temperature.
After removal of the solvent, the residue was adjusted to pH 14 by NaOH aqueous solution,
and extracted with CHCl3 (5 × 15 mL). The organic phase was collected and dried over
Na2SO4. After removal of the solvent, the desired colorless solid was obtained in 95.4%
yield.
1,1,3,3-tetraphenylyloxy-5,5,-bikis[4-(1,4,7,10-tetraazacyclododecanyl)methylph
enoxy]cyclotriphosphazene (5a): 1H NMR (CDCl3): δ 7.45 (dd, 4H, -C6H4, J = 7.6 Hz),
7.38 (m, 4H, -C12H8), 7.29 (m, 12H, -C12H8), 7.10 (d, 4H, -C6H4, J = 7.6 Hz), 3.67 (s,
4H, -CH2-Ph), 2.78 (t, 8H, -CH2-cyclen, J = 4.4 Hz), 2.66 (d, 8H, -CH2-cyclen, J = 5.6
Hz), 2.62 (d, 8H, -CH2-cyclen, J = 5.6 Hz), 2.56 (t, 8H, -CH2-cyclen, J = 5.2 Hz); 13C
NMR (CDCl3): δ 149.9, 148.3, 135.7, 130.1, 129.6, 129.5, 128.7, 126.0, 121.8, 121.0,
58.9, 51.4, 47.6, 46.3, 45.7; 31P NMR (CDCl3): δ 25.6 (d, -P(O2C12H8)2, J = 91.5 Hz),
9.2 (t, P(-O-C6H4-)2, J = 89.3 Hz); ESI-MS: m/z 1058 [M+H]+.